Daily multiple insulin injections (MDI) therapy is a well-established intensive therapy, and this basal-bolus therapy is the best therapeutic option for patients with T1DM for a long time, until emergence and development of continuous subcutaneous insulin infusion (CSII) using insulin pumps. The gene discussed is INS; the disease is type 1 diabetes mellitus.